Blood Plasma Derivatives Market Report 2026

The blood plasma derivatives market size has grown strongly in recent years. It will grow from $55.76 billion in 2025 to $60.76 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to increasing diagnosis of rare blood disorders, expansion of plasma collection programs, rising demand for albumin therapies, improvements in plasma fractionation techniques, growing hospital-based plasma usage.

The blood plasma derivatives market size is expected to see strong growth in the next few years. It will grow to $86.68 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing prevalence of immunodeficiency diseases, rising investments in plasma-derived therapeutics, expansion of global plasma donation networks, growing focus on self-sufficiency in plasma supply, advancements in recombinant protein technologies. Major trends in the forecast period include increasing demand for immunoglobulin therapies, rising adoption of recombinant plasma products, expansion of fractionation and purification technologies, growing focus on pathogen reduction processes, enhanced cold chain and plasma processing efficiency.

The rising prevalence of hemophilia is expected to boost the growth of the blood plasma derivatives market. Hemophilia is a hereditary bleeding disorder that prevents blood from clotting properly, which can lead to spontaneous bleeding as well as bleeding following injury or surgery. In individuals with hereditary or acquired hemostasis disorders, blood plasma-derived products or medications can effectively enhance clotting. Treatments for hemophilia A, von Willebrand disease, and hemophilia B involve the use of factor VIII, factor VIII/vWF, and factor IX concentrates, respectively. For example, in October 2025, the World Federation of Hemophilia (WFH) Annual Global Survey (AGS) reported that in 2024, there was a 6% increase in the global identification of individuals with hemophilia, a 6% increase in those diagnosed with VWD, and a 9% increase in the detection of other inherited bleeding disorders. As a result, the growing prevalence of hemophilia is driving the expansion of the blood plasma derivatives market.

Major companies operating in the blood plasma derivatives market are concentrating on supply chain innovations such as intravenous immunoglobulin, which supports the immune system by providing functional antibodies to patients with immunodeficiency. Intravenous immunoglobulin (IVIg) is a medication made from purified antibodies collected from the plasma of thousands of healthy donors to modulate the immune system. For example, in August 2025, Octapharma, a Switzerland-based human protein products company specializing in plasma-derived and recombinant therapies, launched Gamten 10% IVIg under the UK Plasma for Medicines Programme. This intravenous immunoglobulin (IVIg) product, derived from UK-donated human plasma, is designed to provide immunoglobulin replacement therapy for patients with primary or secondary immunodeficiency. In addition, the company offers specialty therapies, including coagulation factors and treatments for critical care conditions.

In October 2025, Accord Plasma B.V., a Netherlands-based pharmaceutical company, acquired Prothya Biosolutions Belgium BV for an undisclosed amount. Through this acquisition, Accord gained full ownership of Prothya’s plasma fractionation facilities and plasma collection network, expanded its global plasma-derived medicine capabilities, and strengthened its presence in Europe. Prothya Biosolutions is a Belgium-based biopharmaceutical company that produces various human blood plasma-derived medicinal products for use in immunology and critical care therapies.

Major companies operating in the blood plasma derivatives market are Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Limited, Meiji Group, Grifols S.A., Shire Pharmaceuticals Inc., GC Biopharma Corp, Emergent BioSolutions Inc., Shanghai Raas Blood Products Co Ltd., Kedrion S.p.A., Sanquin, Biotest AG, Bio Products Ltd., ADMA Biologics Inc., China Biologic Products Holdings Inc., BioIVT, PlasmaGen BioSciences Pvt. Ltd., Virchow Biotech Private Limited, LFB S.A., Intas Pharmaceuticals Ltd., Octapharma Plasma.

North America was the largest region in the blood plasma derivatives market in 2025. The regions covered in the blood plasma derivatives market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blood plasma derivatives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the blood plasma derivatives market by increasing costs of imported fractionation equipment, purification systems, cold storage infrastructure, and specialized processing materials. Plasma manufacturers and hospitals in North America and Europe are most affected due to dependence on imported processing technologies, while Asia-Pacific faces cost pressures on plasma product exports. These tariffs are increasing production and compliance costs and impacting supply availability. However, they are also promoting domestic plasma processing investments, regional manufacturing expansion, and long-term resilience in plasma derivative supply chains.

The blood plasma derivatives market research report is one of a series of new reports that provides blood plasma derivatives market statistics, including blood plasma derivatives industry global market size, regional shares, competitors with a blood plasma derivatives market share, detailed blood plasma derivatives market segments, market trends and opportunities, and any further data you may need to thrive in the blood plasma derivatives industry. This blood plasma derivatives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blood plasma derivatives are therapeutic products made from purified proteins found in blood plasma, including clotting factors, albumins, and other proteins used to manage various medical conditions. These derivatives are highly important as they help restore deficient or missing proteins in the body.

The primary types of blood plasma derivatives include albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. Albumin is a vital protein in blood plasma derivatives that helps maintain osmotic pressure in the blood and assists in transporting hormones, metals, and other molecules throughout the body. These derivatives are applied in the treatment of conditions such as hemophilia, hypogammaglobulinemia, immunodeficiency disorders, von Willebrand's disease, and others, and are utilized by various end-users, including hospitals, clinics, and more.

The blood plasma derivatives market consists of sales of fibrinogen, globulin, sodium, potassium, bicarbonate, and chloride. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.